Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 8/2018

01-08-2018 | Original Article – Cancer Research

Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model

Authors: Vivian Adamski, Christina Schmitt, Florian Ceynowa, Rainer Adelung, Ralph Lucius, Michael Synowitz, Kirsten Hattermann, Janka Held-Feindt

Published in: Journal of Cancer Research and Clinical Oncology | Issue 8/2018

Login to get access

Abstract

Purpose

Glioblastoma multiforme (GBM) is a poorly curable disease due to its heterogeneity that enables single cells to survive treatment regimen and initiate tumor regrowth. Although some progress in therapy has been achieved in the last years, the efficient treatment of GBMs is still a clinical challenge. Besides the standard therapeutic drug temozolomide (TMZ), quinoline-based antimalarial drugs such as hydroxychloroquine (HCQ) and BH3 mimetics such as AT101 were considered as possible drugs for GBM therapy.

Methods

We investigated the effects of sequentially applied single and combined TMZ, HCQ and AT101 treatments in a long-term stimulation GBM in vitro model. We performed all investigations in parallel in human astrocytes and two differentially TMZ-responsive human GBM cell lines and adjusted used drug concentrations to known liquor/plasma concentrations in patients. We determined amounts of dead cells and still remaining growth rates and depicted our results in a heatmap-like summary to visualize which sequential long-term treatment schedule seemed to be most promising.

Results

We showed that sequential stimulations yielded higher cytotoxicity and better tumor growth control in comparison to single TMZ treatment. This was especially the case for the sequences TMZ/HCQ and TMZ + AT101/AT101 which was as effective as the non-sequential combination TMZ + AT101. Importantly, those affected both less and more TMZ-responsive glioma cell lines, whilst being less harmful for astrocytes in comparison to single TMZ treatment.

Conclusions

Sequential treatment with mechanistically different acting drugs might be an option to reduce side effects in long-term treatment, for example in local administration approaches.
Appendix
Available only for authorised users
Literature
go back to reference Adamski V, Hempelmann A, Flüh C, Lucius R, Synowitz M, Hattermann K, Held-Feindt J (2017) Dormant human glioblastoma cells acquire stem cell characteristics and are differentially affected by temozolomide and AT101 treatment strategies. Oncotarget 8:108064–108078CrossRefPubMedPubMedCentral Adamski V, Hempelmann A, Flüh C, Lucius R, Synowitz M, Hattermann K, Held-Feindt J (2017) Dormant human glioblastoma cells acquire stem cell characteristics and are differentially affected by temozolomide and AT101 treatment strategies. Oncotarget 8:108064–108078CrossRefPubMedPubMedCentral
go back to reference Antonietti P, Linder B, Hehlgans S, Mildenberger IC, Burger MC, Fulda S, Steinbach JP, Gessler F, Rödel F, Mittelbronn M, Kögel D (2017) Interference with the HSF1/HSP70/BAG3 pathway primes glioma cells to matrix detachment and BH3 mimetic-induced apoptosis. Mol Cancer Ther 16:156–168CrossRefPubMed Antonietti P, Linder B, Hehlgans S, Mildenberger IC, Burger MC, Fulda S, Steinbach JP, Gessler F, Rödel F, Mittelbronn M, Kögel D (2017) Interference with the HSF1/HSP70/BAG3 pathway primes glioma cells to matrix detachment and BH3 mimetic-induced apoptosis. Mol Cancer Ther 16:156–168CrossRefPubMed
go back to reference Arevalo Á, Erices J, Uribe D, Howden J, Niechi I, Muñoz S, Martín R, Monrás C (2017) Current therapeutic alternatives and new perspectives in glioblastoma multiforme. Curr Med Chem 24:2781–2795CrossRefPubMed Arevalo Á, Erices J, Uribe D, Howden J, Niechi I, Muñoz S, Martín R, Monrás C (2017) Current therapeutic alternatives and new perspectives in glioblastoma multiforme. Curr Med Chem 24:2781–2795CrossRefPubMed
go back to reference Bae SH, Park M-J, Lee MM, Kim M, Lee S-H, Cho SY, Kim Y-H, Kim YJ, Park C-K, Kim C-Y (2014) Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. J Korean Med Sci 29:980–984CrossRefPubMedPubMedCentral Bae SH, Park M-J, Lee MM, Kim M, Lee S-H, Cho SY, Kim Y-H, Kim YJ, Park C-K, Kim C-Y (2014) Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. J Korean Med Sci 29:980–984CrossRefPubMedPubMedCentral
go back to reference Bonovia R, Inda M, Cavenee W, Furnari F (2011) Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 71:4055–4060CrossRef Bonovia R, Inda M, Cavenee W, Furnari F (2011) Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 71:4055–4060CrossRef
go back to reference Bricenõ E, Calderon A, Sotelo J (2007) Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 67:388–391CrossRefPubMed Bricenõ E, Calderon A, Sotelo J (2007) Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 67:388–391CrossRefPubMed
go back to reference Bushunow P, Reidenberg MM, Wasenko J, Winfiled J, Lorenzo B, Lemke S, Himpler B, Corona R, Coyle T (1999) Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol 43:79–86CrossRefPubMed Bushunow P, Reidenberg MM, Wasenko J, Winfiled J, Lorenzo B, Lemke S, Himpler B, Corona R, Coyle T (1999) Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol 43:79–86CrossRefPubMed
go back to reference Chou TC (2010) Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Res 70:440–446CrossRefPubMed Chou TC (2010) Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Res 70:440–446CrossRefPubMed
go back to reference Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55CrossRefPubMed Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55CrossRefPubMed
go back to reference Golden EB, Cho H-Y, Hofman FM, Louie S, Schönthal AH, Chen TC (2015) Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus 38:E12CrossRefPubMed Golden EB, Cho H-Y, Hofman FM, Louie S, Schönthal AH, Chen TC (2015) Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus 38:E12CrossRefPubMed
go back to reference Gunja N, Roberts D, McCoubrie D, Lamberth P, Jan A, Simes DC, Hackett P, Buckley NA (2009) Survival after massive hydroxychloroquine overdose. Anaesth Intensive Care 37:130–133PubMed Gunja N, Roberts D, McCoubrie D, Lamberth P, Jan A, Simes DC, Hackett P, Buckley NA (2009) Survival after massive hydroxychloroquine overdose. Anaesth Intensive Care 37:130–133PubMed
go back to reference Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ (2010) Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 5:1637–1643CrossRefPubMed Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ (2010) Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol 5:1637–1643CrossRefPubMed
go back to reference Henriksen S, Tylden GD, Dumoulin A, Sharma BN, Hirsch HH, Hanssen Rinaldo C (2014) The human fetal glial cell line SVG p12 contains infectious BK polyomavirus. J Virol 88:7556–7768CrossRefPubMedPubMedCentral Henriksen S, Tylden GD, Dumoulin A, Sharma BN, Hirsch HH, Hanssen Rinaldo C (2014) The human fetal glial cell line SVG p12 contains infectious BK polyomavirus. J Virol 88:7556–7768CrossRefPubMedPubMedCentral
go back to reference Hsu SPC, Kuo JS, Chiang HC, Wang HE, Wang YS, Huang CC, Huang YC, Chi MS, Mehta MP, Chi KH (2018) Temozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and cholesterol homeostasis in GBM cells. Oncotarget 9:6883–6896PubMedPubMedCentral Hsu SPC, Kuo JS, Chiang HC, Wang HE, Wang YS, Huang CC, Huang YC, Chi MS, Mehta MP, Chi KH (2018) Temozolomide, sirolimus and chloroquine is a new therapeutic combination that synergizes to disrupt lysosomal function and cholesterol homeostasis in GBM cells. Oncotarget 9:6883–6896PubMedPubMedCentral
go back to reference Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shiels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT (2014) Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumor models. Br J Cancer 11:2275–2286CrossRef Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shiels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT (2014) Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumor models. Br J Cancer 11:2275–2286CrossRef
go back to reference Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S (2004) Role of autophagy in temozolomide induced cytotoxicity for malignant glioma cells. Cell Death Differ 11:448–457CrossRefPubMed Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S (2004) Role of autophagy in temozolomide induced cytotoxicity for malignant glioma cells. Cell Death Differ 11:448–457CrossRefPubMed
go back to reference Katayama M, Kawaguchi T, Berger MS, Pieper RO (2007) DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14:548–558CrossRefPubMed Katayama M, Kawaguchi T, Berger MS, Pieper RO (2007) DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14:548–558CrossRefPubMed
go back to reference Keshmiri-Neghab H, Goliaei B, Nikoofar A (2014) Gossypol enhances radiation-induced autophagy in glioblastoma multiforme. Gen Physiol Biophys 33:433–442CrossRefPubMed Keshmiri-Neghab H, Goliaei B, Nikoofar A (2014) Gossypol enhances radiation-induced autophagy in glioblastoma multiforme. Gen Physiol Biophys 33:433–442CrossRefPubMed
go back to reference Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3:198e210 Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3:198e210
go back to reference Lee SW, Kim HK, Lee NH, Yi HY, Kim HS, Hong SH, Hong YK, Joe YA (2015) The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. Cancer Lett 360:195–204CrossRefPubMed Lee SW, Kim HK, Lee NH, Yi HY, Kim HS, Hong SH, Hong YK, Joe YA (2015) The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. Cancer Lett 360:195–204CrossRefPubMed
go back to reference Li S, Jiang T, Li G, Wang Z (2008) Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. Neurol Res 30:567–570CrossRefPubMed Li S, Jiang T, Li G, Wang Z (2008) Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. Neurol Res 30:567–570CrossRefPubMed
go back to reference Lu Y, Li J, Dong C-E, Hunag J, Zhou H-B, Wang W (2017) Recent advances in gossypol derivatives and analogs: a chemistry and biology view. Future Med Chem 9:1243–1275CrossRefPubMed Lu Y, Li J, Dong C-E, Hunag J, Zhou H-B, Wang W (2017) Recent advances in gossypol derivatives and analogs: a chemistry and biology view. Future Med Chem 9:1243–1275CrossRefPubMed
go back to reference Opydo-Chanek M, Gonzola O, Marzo I (2017) Multifaceted anticancer activity of BH3 mimetics: current evidence and future prospects. Biochem Pharmacol 136:12–23CrossRefPubMed Opydo-Chanek M, Gonzola O, Marzo I (2017) Multifaceted anticancer activity of BH3 mimetics: current evidence and future prospects. Biochem Pharmacol 136:12–23CrossRefPubMed
go back to reference Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, Stupp R (2004) Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10:3728–3736CrossRefPubMed Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, Stupp R (2004) Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10:3728–3736CrossRefPubMed
go back to reference Parazzoli G, Prados J, Ortiz R, Caba O, Cabeza L, Berdasco M, Gónzalez B, Melguizo C (2015) Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression. PLoS One 10:e0140131CrossRef Parazzoli G, Prados J, Ortiz R, Caba O, Cabeza L, Berdasco M, Gónzalez B, Melguizo C (2015) Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression. PLoS One 10:e0140131CrossRef
go back to reference Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, Piao S, Troxel AB, Evans TL, DeMichele AM, Nathanson KL, O’Dwyer PJ, Kaiser J, Pontiggia L, Davis LE, Amaravadi RK (2014) Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10:1369–1379CrossRefPubMedPubMedCentral Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, Piao S, Troxel AB, Evans TL, DeMichele AM, Nathanson KL, O’Dwyer PJ, Kaiser J, Pontiggia L, Davis LE, Amaravadi RK (2014) Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10:1369–1379CrossRefPubMedPubMedCentral
go back to reference Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, McAfee Q, Fisher J, Troxel AB, Piao S, Heitjan DF, Tan KS, Pontiggia L, O’Dwyer PJ, Davis LE, Amaravadi RK (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10:1359–1368CrossRefPubMedPubMedCentral Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, McAfee Q, Fisher J, Troxel AB, Piao S, Heitjan DF, Tan KS, Pontiggia L, O’Dwyer PJ, Davis LE, Amaravadi RK (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10:1359–1368CrossRefPubMedPubMedCentral
go back to reference Schelman WR, Mohammed TA, Traynor AM, Kolesar JM, Marnocha RM, Eickhoff J, Keppen M, Alberti DB, Wilding G, Takebe N, Liu G (2014) A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Investig New Drugs 32:295–302CrossRef Schelman WR, Mohammed TA, Traynor AM, Kolesar JM, Marnocha RM, Eickhoff J, Keppen M, Alberti DB, Wilding G, Takebe N, Liu G (2014) A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Investig New Drugs 32:295–302CrossRef
go back to reference Schweighardt B, Shieh JT, Atwood WJ (2001) CD4/CXCR4-independent infection of human astrocytes by a T-tropic strain of HIV-1. J Neurovirol 7:155–162CrossRefPubMed Schweighardt B, Shieh JT, Atwood WJ (2001) CD4/CXCR4-independent infection of human astrocytes by a T-tropic strain of HIV-1. J Neurovirol 7:155–162CrossRefPubMed
go back to reference Shen S, Wu Y, Li K, Wang Y, Wu J, Zeng Y, Wu D (2018) Versatile hyaluronic acid modified AQ4N-Cu(II)-gossypol infinite coordination polymer nanoparticles: multiple tumor targeting, highly efficient synergistic chemotherapy, and real-time self-monitoring. Biomaterials 154:197–212CrossRefPubMed Shen S, Wu Y, Li K, Wang Y, Wu J, Zeng Y, Wu D (2018) Versatile hyaluronic acid modified AQ4N-Cu(II)-gossypol infinite coordination polymer nanoparticles: multiple tumor targeting, highly efficient synergistic chemotherapy, and real-time self-monitoring. Biomaterials 154:197–212CrossRefPubMed
go back to reference Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Wood BA, Brookes M, Leopold L (2012) Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 23:1803–1808CrossRefPubMed Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Wood BA, Brookes M, Leopold L (2012) Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol 23:1803–1808CrossRefPubMed
go back to reference Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed
go back to reference Voss V, Senft C, lang V, Ronellenfitsch MW, Steinbach JP, Seifert V, Kögel D (2010) The pan-Bcl-2 inhibitor (−)gossypol triggers autophagic cell death in malignant gliomas. Mol Cancer Res 8:1002–1016CrossRefPubMed Voss V, Senft C, lang V, Ronellenfitsch MW, Steinbach JP, Seifert V, Kögel D (2010) The pan-Bcl-2 inhibitor (−)gossypol triggers autophagic cell death in malignant gliomas. Mol Cancer Res 8:1002–1016CrossRefPubMed
go back to reference Wang Y, Shi K, Zhang L, Hu G, Wan J, Tang J, Yin S, Duan J, Qin M, Wang N, Xie D, Gao X, Gao H, Zhang Z, He Q (2016) Significantly enhanced tumor cellular and lysosomal hydroxychloroquine delivery by smart liposomes for optimal autophagy inhibition and improved antitumor efficiency with liposomal doxorubicin. Autophagy 12:949–962CrossRefPubMedPubMedCentral Wang Y, Shi K, Zhang L, Hu G, Wan J, Tang J, Yin S, Duan J, Qin M, Wang N, Xie D, Gao X, Gao H, Zhang Z, He Q (2016) Significantly enhanced tumor cellular and lysosomal hydroxychloroquine delivery by smart liposomes for optimal autophagy inhibition and improved antitumor efficiency with liposomal doxorubicin. Autophagy 12:949–962CrossRefPubMedPubMedCentral
go back to reference Warnsmann V, Meyer N, Hamann A, Kögel D, Osiewacz (2018) A novel role of the mitochondrial permeability transition pore in (−)gossypol-induced mitochondrial dysfunction. Mech Ageing Dev 170:45–58CrossRefPubMed Warnsmann V, Meyer N, Hamann A, Kögel D, Osiewacz (2018) A novel role of the mitochondrial permeability transition pore in (−)gossypol-induced mitochondrial dysfunction. Mech Ageing Dev 170:45–58CrossRefPubMed
go back to reference Zerp SF, Stoter TR, Hoebers FJP, van den Brekel MWM, Dubbelman R, Kuipers GK, Lafleur MVM, Slotman BJ, Verheij M (2015) Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer. Radiat Oncol 10:158CrossRefPubMedPubMedCentral Zerp SF, Stoter TR, Hoebers FJP, van den Brekel MWM, Dubbelman R, Kuipers GK, Lafleur MVM, Slotman BJ, Verheij M (2015) Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer. Radiat Oncol 10:158CrossRefPubMedPubMedCentral
Metadata
Title
Effects of sequentially applied single and combined temozolomide, hydroxychloroquine and AT101 treatment in a long-term stimulation glioblastoma in vitro model
Authors
Vivian Adamski
Christina Schmitt
Florian Ceynowa
Rainer Adelung
Ralph Lucius
Michael Synowitz
Kirsten Hattermann
Janka Held-Feindt
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 8/2018
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-018-2680-y

Other articles of this Issue 8/2018

Journal of Cancer Research and Clinical Oncology 8/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.